[ad_1]
Geneva, Switzerland, July 7, 2021 —— Addex therapy (SIX:ADXN) is a clinical-stage pharmaceutical company that pioneered drug discovery and development based on allosteric modulation. Today it announced that CEO Tim Dyer will attend Access to Giving at 9 am Eastern Time on July 14, 2021 Virtual meeting. Mr. Dyer will provide the company’s latest news, including an overview of the recent progress of the Addex clinical trial program. The conference is free for all registrants.
Registration details
Date: Wednesday, July 14, 2021
Time: 9 a.m. Eastern Time
Association: https://access-to-giving.events.issuerdirect.com/signup
To learn more about the event or to schedule a one-on-one meeting with Addex management, please visit https://www.accesstogiving.com/ Or email james@haydenir.com.
About Addex Therapeutics
Addex therapy It is a clinical stage pharmaceutical company focusing on the development and commercialization of a new class of new oral small molecule drugs, called allosteric modulators of neurological diseases. Allosteric modulators have several potential advantages over traditional non-allosteric molecules, and can provide an improved treatment method for traditional “orthogonal” small molecules or biopharmaceuticals. Addex’s allosteric modulator drug discovery platform targets receptors and other proteins that are considered…
The full story on Benzinga.com
[ad_2]
Source link
